Silencing DVL3 defeats MTX resistance and attenuates stemness via Notch Signaling Pathway in colorectal cancer.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 23 01 2020
revised: 20 03 2020
accepted: 11 04 2020
pubmed: 18 5 2020
medline: 15 5 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

Chemoresistance and recurrence of colorectal cancer are mainly caused by the existence of cancer stem-like cells. Dishevelled-3 (DVL3) is a common member of both Wnt/β-catenin pathway and the Notch signaling pathway, which were involved in cancer progression, chemoresistance and even maintenance of stem cell-like properties. However, the underlying biological function of DVL3 still remains unclear. In this study, we proposed DVL3 was simultaneously involved in Methotrexate (MTX) resistance and Colorectal cancer (CRC) stemness by bioinformatic analysis. We also demonstrated DVL3 knockdown sensitized CRC cells to MTX and inhibited their stem cell-like properties by functional experiments. As for the mechanism, DVL3 silencing attenuated the activated Notch signaling by down-regulating Notch intracellular domain (NICD) as well as its downstream targets. Additionally, we demonstrated that CRC cancer tissues had greater DVL3 expression than adjacent non-cancer tissues and patients' overall survival was closely associated with DVL3 according to the data in our clinical center. Accordingly, our data suggest that DVL3 is a key regulator in CRC stemness and chemoresistance and targeting DVL3 could be a potential strategy for CRC therapy.

Identifiants

pubmed: 32414668
pii: S0344-0338(20)30241-7
doi: 10.1016/j.prp.2020.152964
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
DVL3 protein, human 0
Dishevelled Proteins 0
Receptors, Notch 0
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

152964

Informations de copyright

Copyright © 2020 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Qian Zhao (Q)

Department of Gastroenterology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, PR China.

Kun Zhuang (K)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China.

Kun Han (K)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China.

Hailing Tang (H)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China.

Yu Wang (Y)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China.

Wangli Si (W)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China.

Zhenwei Yang (Z)

Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710061, PR China. Electronic address: yangzhenwei513@sina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH